Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, you can pause Mounjaro, but the evidence is clear that stopping — even briefly — tends to reverse the appetite and weight changes the medicine was producing. Most people regain weight when they stop, and the speed of regain varies widely. Mounjaro is a prescription-only medicine; any decision to pause, stop or restart should be made with your prescriber rather than independently. Here is what the clinical picture actually looks like, and what questions are worth raising before you decide.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people arrive at this question believing that pausing Mounjaro for a week or two will give the treatment a chance to "reset", that stepping away briefly might make it work better on return, or that the body needs periodic breaks from any medicine. It is a reasonable-sounding idea, and it is worth letting it go gently, because the clinical evidence points in the other direction.
Tirzepatide, the active molecule in Mounjaro, works while it is present in your system. It acts on the GIP and GLP-1 receptors that regulate appetite, feelings of fullness and gastric emptying. Those effects diminish as the medicine clears, which happens gradually over the days following a missed dose. Hunger and portion size typically start climbing back toward baseline within a week or two for many people. The NHS medicines page for tirzepatide notes that Mounjaro is intended for ongoing use alongside dietary and activity changes, not as an intermittent course.
A one-week break is unlikely to cause lasting harm, but it is also unlikely to produce any clinical benefit. What it can produce is a noticeable return of appetite that some people find disorienting, particularly if they had settled well at their current dose. That is not a reason to feel alarmed, it is simply the medicine doing less of its job while it is absent.
The longer a break, the more significant the potential for weight regain. The evidence base here is substantial. Extension and withdrawal data from the SURMOUNT programme showed that people who stopped tirzepatide regained a meaningful proportion of the weight they had lost, typically within a year, while those who continued maintained their results. This mirrors what was seen with semaglutide in the STEP 1 extension trial, published in the New England Journal of Medicine, where participants regained around two-thirds of lost weight within a year of stopping.
This is not a failure of willpower. It reflects the underlying biology of obesity, the hormonal and metabolic signals that drive hunger do not permanently change after a course of treatment. You can read more about this in our Mounjaro overview, which covers how the medicine works and what the evidence shows about sustained use.
If you have been on Mounjaro for several months and are thinking about a planned break for reasons of cost or convenience, that conversation is worth having with your prescriber before acting. They can help you weigh the likely trajectory against alternatives, including whether a lower maintenance dose might be more sustainable long-term.
Some breaks are planned; others are not. Surgery is one of the more common reasons a prescriber or anaesthetist will ask you to stop before a procedure, because GLP-1 receptor agonists slow gastric emptying and there are anaesthesia considerations involved. NHS England's guidance on weight management injections notes that patients should inform their surgical team and anaesthetist that they are taking this class of medicine. Your prescriber should be involved in the timing.
If you are pausing because of a side effect (persistent nausea, gastrointestinal discomfort, or anything more serious) that is a clinical conversation rather than something to manage alone. A prescriber may recommend staying at your current dose longer rather than stopping, or adjusting something else in your regimen. If you experienced something that genuinely alarmed you, contact your prescriber or GP promptly.
A short break because a pen has not arrived, or because you are travelling for a week, is a different situation again. Missing a single injection is not an emergency. If you are wondering whether timing a dose a day differently might help, that question is covered separately for taking a dose slightly early. For breaks of closer to three weeks, the considerations become more involved, our page on taking a three-week break from Mounjaro covers that specific situation in more detail.
If you do stop and later want to restart, restarting is generally possible, subject to clinical assessment. The key question is how long the break was. A gap of a week or so typically does not require a dose reduction. A longer gap, particularly several weeks or more, often means starting from a lower dose again to let your system readjust and reduce the chance of side effects hitting hard on return, the same tolerability logic that applies at the start of treatment.
This is one reason it is worth being transparent with your prescriber about any interruption. At nume, every repeat order is reviewed by a GPhC-registered prescriber before it is approved, so if your pattern of use has changed, that conversation happens naturally as part of the process.
If you are at the stage of wondering whether Mounjaro is the right treatment for you at all, or whether you meet the eligibility criteria, our page on who can take Mounjaro covers the licensed criteria in detail. And if you have questions about accessing treatment, including whether you can get Mounjaro from your GP and how BMI and any existing conditions are assessed, what BMI is needed for Mounjaro is a good starting point.
If you are ready to discuss your specific situation with a prescriber, speak to our prescribers via a free consultation, our clinical team reviews each case the same day it arrives.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.